Ghosh, Paramita M., Margarita Mikhailova, Roble Bedolla, and Jeffrey I. Kreisberg. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol 280: F972-F979, 2001.-The potent vasoconstrictor arginine vasopressin (AVP) is also a mitogen for mesangial cells. Treatment with AVP decreased transit time through the cell cycle. AVP-stimulated mesangial cell growth by activating both the Ras mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K) cell signaling pathways. Both the selective PI3K inhibitor LY-294002 and the MAPK kinase (MEK) inhibitor PD-98059 inhibited AVPstimulated mesangial cell proliferation. However, LY-294002 was more potent, indicating an important role for PI3K activation in AVP-stimulated mesangial cell proliferation. AVP appeared to exert its effect on MAPK and PI3K activation, as well as on cell proliferation, by activating the epidermal growth factor receptor (EGF-R). Pretreatment with the tyrphostin-derived EGF-R antagonist AG-1478 inhibited mesangial cell proliferation as well as the activation of extracellular signal-regulated kinase 1/2 (ERK1/2 or p42/ p44 MAPK ), and p70S6 kinase, a downstream effector of PI3K, providing evidence that MAPK and PI3K activation, respectively, occurred downstream of EGF-R activation. Treatment with rapamycin, an inhibitor of the p70S6 kinase activator mTOR, also resulted in growth inhibition, further suggesting the importance of the PI3K signaling pathway in AVP-induced proliferation. AVP treatment appeared to transactivate EGF-R by inducing tyrosine phosphorylation of the Ca 2ϩ /protein kinase C (PKC)-dependent nonreceptor tyrosine kinase, Pyk2, leading to Pyk2/c-Src association and c-Src activation. This was followed by association of c-Src with EGF-R and EGF-R activation. These data suggested that AVP-stimulated Pyk2 tyrosine phosphorylation to activate c-Src, thereby leading to EGF-R transactivation.
in maintaining the microcirculation of the glomerulus. During the course of injury, mesangial cells are exposed to a variety of mediators, which are either released locally or are present in the systemic circulation. Among these are platelet-derived growth factor B chain (PDGF-BB), epidermal growth factor (EGF), endothelin-1 (ET-1), angiotensin II (ANG II), interleukin-1 and -6, and arginine vasopressin (AVP), all of which have been shown to be mitogens for mesangial cells in culture (10, 20, 22) . It is not surprising, given the importance of mesangial cell proliferation in a variety of glomerular diseases, that a considerable effort has been undertaken to elucidate the mechanisms of glomerular cell proliferation in the hope of designing new specific and effective therapies (49) .
Vasoactive agents such as AVP, ANG II, and ET-1 modulate vascular tone and glomerular filtration through their contractile effects on glomerular mesangial cells (20, 22, 42) . Additionally, these agents induce hypertrophy and cell growth in both mesangial and smooth muscle cells (22, 25, 54) . AVP, rather than ANG II, has been shown to be a potent inducer of mesangial cell proliferation (42) . Mesangial cells express the vasopressin V 1 receptor, which, when stimulated, induces mobilization of intracellular Ca 2ϩ , rather than the V 2 receptor, which results in elevations in cAMP levels on stimulation (8, 27) . Several lines of evidence indicate the involvement of AVP in proliferative glomerular injury. Chronic blockade of the vasopressin V 1 receptor directly inhibits glomerular proliferative injury in salt-loaded spontaneously hypertensive rats (SHR) (36) and in rats showing manifestations of hypercholesterolemia and protein urea (33) . In addition, glomeruli of SHR possess a higher number of AVP receptors (V 1 ) than do glomeruli of age-matched Wistar-Kyoto (WKY) rats (36) . These results suggest that AVP induces proliferation in glomerular mesangial cells through activation of its V 1 receptor. Studies from our laboratory showed that, on binding to its specific V 1 receptor, AVP activates a phosphatidylinositol-specific-phospholipase C (PI-PLC) in rat mesangial cells (46) . This results in ele-vated levels of inositol trisphosphate (IP 3 ) and diacylglycerol (DAG), leading to mobilization of intracellular stores of Ca 2ϩ and stimulation of protein kinase C (PKC) (4, 52) . Ca 2ϩ mobilization and PKC activation induce increased cell signaling, leading to cell cycle progression (23, 45) . These results suggest that AVPstimulated proliferation may be mediated by Ca 2ϩ mobilization and PKC activation.
In contrast to tyrosine kinase receptors like the PDGF-BB receptor (PDGF-R␤), vasoactive agents such as AVP, ANG II, and endothelin exert their affect by binding G protein-coupled receptors (GPCR) that lack cytoplasmic tyrosine kinase domains. However, like classic growth factors, tyrosine phosphorylation plays a critical role in the growth response elicited by these vasoactive agents (20, 25) . Activation of GPCR causes tyrosine phosphorylation of adaptor proteins, such as Shc, Src, or IRS-1, leading to activation of p21
Ras and phosphatidylinositol 3-kinase (PI3K). This results in stimulation of the effectors of Ras and PI3K: the mitogen activated protein kinase (MAPK) and p70S6 kinase signaling pathways, respectively (16, 21, 41) . The mechanism of adaptor protein activation by the vasopressin V 1 receptor is presently unknown.
In this report we show that AVP stimulates mesangial cell proliferation by activating the EGF receptor (EGF-R). EGF-R activation stimulates mesangial cell growth by activating both the Ras/MAPK and PI3K signaling pathways, which results in activation of their downstream effectors, extracellular signal-regulated kinase (ERK) and p70S6 kinase. Importantly, it appears that GPCR activation of the EGF-R is transduced by the Ca 2ϩ /PKC-dependent nonreceptor tyrosine kinase Pyk2, which results in c-Src activation of the EGF-R. Our results attempt to elucidate the signaling steps leading from AVP-induced stimulation of the V 1 receptor to cell proliferation.
MATERIALS AND METHODS
Cell culture and pharmacological treatments. Rat mesangial cells were isolated and established in culture as previously described (32) . The cells were cultured in RPMI 1640 containing 20% fetal bovine serum (FBS) and 1% antimycotic-antibiotic solution (Mediatech-Cellgro). AG 1478, rapamycin, PD-98059, and LY-294002 were obtained from Calbiochem, La Jolla, CA. AVP was from Sigma, St. Louis, MO, and EGF was obtained from GIBCO. Rabbit polyclonal anti-phospho-ERK (Thr 202 /Tyr 204 ) and anti-phospho-Akt (Ser 473) antibody were from Cell Signaling Technology, Beverly, MA. Monoclonal anti-phosphotyrosine, anti-PDGF-R␤, and antiPyk2 antibodies were from BD Transduction Laboratories, San Diego, CA. Monoclonal anti-c-Src antibody was from Upstate Biotechnology, Lake Placid, NY. All other antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA.
MTT assay. Cells were plated in triplicate in 20% FBS in 24-well plates at a concentration of 10,000 cells/well in the presence of the agonists to be studied (AVP or EGF, at various concentrations). After 24 h of treatment, 60 l 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were added per well. This drug is readily taken up by live cells and is absorbed in the mitochondria, where it is converted to a formazan salt (40) . Although the original drug is yellow in color, the final product is purple. The formazan crystals thus formed are redissolved in 1 ml DMSO. As this conversion can only take place in the mitochondria of live cells, the extent of formazan formation, as detected by the intensity of the color of the final DMSO solution, gives us a good estimate of the number of cells in the well. The effectiveness of growth inducers in stimulating proliferation can be estimated this way, as cells under highly proliferative conditions exhibit a deep purple color while those under less proliferative conditions exhibit a lighter purple. The intensity of the solution was detected by reading in a spectrophotometer (Beckman).
Flow cytometry. Mesangial cells were grown under desired conditions in the presence of 20% FBS in 100-mm dishes at 500,000 cells/dish. Cells to be processed for flow cytometry were trypsinized, then resuspended in 2 ml cell growth medium, and spun down at 1,000 g for 5 min in a tabletop centrifuge. The medium was aspirated, and the pellet was washed once in PBS. The cells were then resuspended in 500 l 70% ethanol and incubated 30 min at Ϫ20°C. The cells were repelleted and washed twice in 1% BSA/PBS. The cells were suspended in 150 l PBS, 50 l of 1 mg/ml RNAse A (Sigma), and 100 l of 100 g/ml propidium iodide (Sigma) and incubated overnight at 4°C. Flow cytometry was conducted on FACStar Plus (Becton Dickinson Immunocytometry Systems, San Jose, CA). Cells were illuminated with 200 mW of 488-nm light produced by an argon-ion laser. Fluorescence was read through a 630/22-nm band-pass filter. Data were collected on 20,000 cells as determined by forward and right-angle light scatter and stored as frequency histograms; data used for cell cycle analysis were then analyzed using MODFIT (Verity software, Topsham, ME).
Western blotting. Mesangial cells were grown on 100-mm dishes at 1,000,000 cells/dish and serum starved for 48 h before the experiments. Whole cell extracts were prepared by washing the cells twice in PBS and lysing cells in 250 l cell lysis buffer (50 mM Tris ⅐ HCl, pH 7.4, 150 mM NaCl, and 10% NP-40, and protease inhibitors: 0.1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml each of phenathroline, leupeptin, aprotinin, and pepstatin A) and phosphatase inhibitors: 20 mM B-glycerol phosphate, 1 mM Na-orthovanadate, and 10 mM NaF. Proteins were quantitated using a BCA assay (Pierce, Rockford IL) and fractionated on SDSpolyacrylamide gels (118:1 acrylamide-bis for p70S6 kinase and 29:1 acrylamide-bis for everything else). Electrophoresis was performed at 45 mA for ϳ45 min using minivertical electrophoresis cells (Mini-PROTEAN II Electrophoresis Cell, Bio-Rad, Hercules, CA). The gels were electroblotted for 1.5 h at 200 mA using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) onto 0.2-m polyvinylidene difluoride membrane (Osmonics, Westborough, MA). The blots were stained with primary antibodies at a dilution of 1:500. The staining was detected by enhanced chemiluminescence (Pierce) after incubation with a peroxidase-labeled secondary antibody (Donkey anti-mouse IgG, Chemicon, Temecula, CA, Goat anti-rabbit IgG, Fc specific, Jackson Immunoresearch Laboratories, West Grove, PA).
Immunoprecipitations. Cells were grown on 100-mm dishes at 500,000 cells/dish and were serum starved for 48 h before the experiment. Five hundred micrograms of protein obtained from whole cell lysates in cell lysis buffer were precleared with 25 l of 50% protein A-Sepharose beads in 400 l of lysis buffer containing 1 g/ml BSA for 1 h. The supernatants were incubated with the appropriate antibody (1-4 g/sample) overnight. Next, 20 l of protein A-Sepharose were added for 1 h, and the immunocomplexes were washed three times with lysis buffer. Samples were sepa-rated by SDS-PAGE, and proteins were detected by Western blotting.
RESULTS
AVP-stimulated proliferation in rat glomerular mesangial cells. We showed previously that AVP stimulated mesangial cell contraction in a Ca 2ϩ -dependent fashion and also induced PKC activation (4, 47) . In addition, AVP (1 M) increased mesangial cell proliferation with a cell doubling time of 34 h compared with 42 h for FCS alone (Fig. 1A) . Fluorescent-activated cell sorting (FACS) analysis revealed that AVP stimulated G1 to S-phase transition with ϳ34% increase of cells in S-phase after 18 h of AVP treatment over and above the effect of FCS alone (Fig. 1B) . The results were normalized to the number of cells in S-phase under control conditions. Dose-response experiments showed that 1 M AVP evoked nearly the same proliferative response in rat mesangial cells as 50 ng/ml EGF (Fig. 2) .
AVP-induced mesangial cell proliferation is mediated by the MAPK and PI3K cell signaling pathways. Mitogenesis in mammalian cells takes place by the activation of either of two signaling pathways: the MAPK or the PI3K pathway. Figure 1B indicates that the PI3K pathway plays a greater role in AVP-induced mitogenesis than the MAPK pathway. Inhibition of the PI3K pathway by the selective PI3K inhibitor LY-294002 (25 M) prevented AVP-stimulated proliferation to a far greater extent (64% decrease in the number of cells in S-phase with respect to AVP treatment alone) than inhibition of the MAPK pathway with the selective inhibitor of MAPK kinase (MEK) PD-98059 (100 M) (28% decrease in the number of cells in S-phase with respect to AVP treatment alone). The drug concentrations used here were determined by the complete inhibition of ERK phosphorylation with PD-98059 and the complete inhibition of Akt phosphorylation by LY-294002 (not shown). In the absence of serum, these inhibitory effects on ERK and Akt phosphorylation were observed with less than 2 h of incubation in the presence of the drug. However, prolonged incubation times were necessary to induce growth arrest in the presence of serum because of the high doubling times of these cells. To determine the effect of AVP alone on the two signaling pathways in rat mesangial cells, we serum starved the cells for 48 h, followed by AVP treatment for 1-60 min. Treatment with AVP for 15 min stimulated both pathways, as evidenced by increased phosphorylation of ERK 1/2 (p42/p44 MAPK ) ( Fig. 3A) and p70S6 kinase, a downstream effector of PI3K (Fig. 3B) . Activation of ERK was determined by immunoblotting with a phosphospecific antibody, whereas p70S6 kinase activation was determined by the appearance of slower migrating forms of the activated protein in SDS-PAGE due to phosphorylation. Phosphorylation of Akt, another downstream effector of PI3K well known for its role in (Fig. 3C) . Treatment with 100 nM rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) kinase indispensable for p70S6 kinase activation, inhibited AVP-induced proliferation (49% decrease in the number of cells in S-phase with respect to AVP treatment alone, Fig. 1B) , suggesting an important role for the PI3K signaling pathway in AVP-induced mesangial cell proliferation.
AVP-induced mesangial cell proliferation requires EGF-R transactivation. GPCRs, like the vasopressin V 1 receptor, lack cytoplasmic tyrosine kinase domains (54) . In other systems, EGF-R was transactivated in response to GPCR activations, and EGF-R appeared to play a central role in relaying mitogenic signals from GPCRs to the nucleus (12) . We therefore determined whether EGF-R was activated in response to AVP treatment as well. Due to its mode of activation, EGF-R activation can be assayed by immunoprecipitation followed by immunoblotting with an anti-phosphotyrosine antibody. As shown in Fig. 4A , mesangial cells displayed EGF-R activation within 15 min of addition of AVP. To determine whether EGF-R activation was necessary for cell proliferation, the cells were treated with the highly selective EGF-R tyrosine kinase inhibitor AG 1478 (20 M). AG 1478 was found to be 30,000 times more selective for EGF-R than for other receptor tyrosine kinases (IC 50 for PDGF-R␤ or other members of the ErbB family ϭ 100 M vs. 3 nM for EGF-R) (19) . Dose-response studies demonstrated that this dose was necessary to significantly reduce cell proliferation in rat mesangial cells in continuous culture (not shown). AG 1478 completely abolished AVP-induced EGF-R activation (Fig. 4B) . On the other hand, AG 1478 did not inhibit the activation of the PDGF-R␤ (Fig. 4C) . Figure 1B shows that 20 M AG 1478 markedly inhibited AVP-stimulated mesangial cell proliferation in the presence of serum (40% decrease in the number of cells in S-phase with respect to AVP treatment alone), thus supporting a role for EGF-R activation in mesangial cell proliferation. AG 1478 inhibited activation of both ERK and p70S6 kinase (Fig. 4D) , indicating that activation of both the MAPK and the (14, 18) . Because AVP has been shown to induce Ca 2ϩ mobilization and PKC activation (4, 20, 23, 47), we determined whether AVP-induced activation of EGF-R in mesangial cells involved activation of Pyk2 and c-Src. Mesangial cell lysates were immunoprecipitated with a Pyk2 antibody, and immunoblots were analyzed with an antibody to phosphotyrosine. AVP treatment for 30 s to 1 min resulted in Pyk2 activation that was sustained through 60 min, as evidenced by tyrosine phosphorylation (Fig. 5A) , with a concomitant transient association of Pyk2 with c-Src determined by immunoprecipitation/immunoblotting experiments (Fig. 5C, top) . AVP treatment also resulted in rapid (within 1 min) tyrosine phosphorylation of c-Src (Fig. 5B ) with its association with EGF-R (Fig.  5C, middle) . EGF-R/c-Src association was determined by immunoprecipitating mesangial cell lysates with an antibody to c-Src and immunoblotting with an antibody to EGF-R. These data suggest that the AVP receptor stimulated Pyk2 tyrosine phosphorylation, resulting in c-Src activation, thereby leading to EGF-R transactivation.
DISCUSSION
Several groups of investigators have reported that AVP is a strong mitogen for mesangial cells (22, 23, 25, 42) . Earlier studies showed that AVP stimulates MAPK activity in mesangial cells (1) and is a very potent inducer of the immediate early genes c-fos, c-jun, and Egr-1 (42) . In this report, we extend these observations and show that AVP treatment of mesangial cells stimulates cell cycle progression and proliferation by inducing PI3K and MAPK activation through a novel mechanism involving the activation of EGF-R (a scheme is shown in Fig. 6 ). Although AVP was shown to stimulate p70S6 kinase activation in rat cardiomyocytes (53) , this is the first time that AVP has A: immunoblot demonstrating activation of EGF-R by AVP. Activation of the EGF-R was determined by immunoprecipitating (IP) cell extracts with an antibody to the EGF-R, and immunoblotting (IB) with an antiphosphotyrosine antibody (pY). Note that EGF-R is activated 15 min after AVP treatment and the level of activation continues to increase for 1 h (top). Total EGF-R levels (bottom), determined by immunoblotting the same membrane with an antibody to EGF-R, are unchanged, indicating equal loading of samples. B: immunoblot demonstrating the effect of the tyrphostin AG1478 (20 M) on EGF-R activation by AVP. RIPA cell extracts were immunoprecipitated with EGF-R antibody, and immunoblots were stained with pY. Notice that AG1478 inhibits EGF-R activation (top). The same immunoblot was stained after stripping for total EGF-R protein to demonstrate equal loading of protein. C: immunoblot demonstrating the effect of AG1478 on [platelet-derived growth factor B chain (PDGF-BB) receptor (PDGF-R␤)] activation. AG 1478 failed to inhibit PDGF-induced PDGF-R activation. Cells were serum starved for 48 h and treated with 10 ng/ml PDGF-BB for 1 h. RIPA cell lysates were immunoprecipitated with monoclonal anti-PDGF-R␤ antibody and immunoblotted with pY. Note that AG1478 failed to inhibit PDGF-R␤ activation. D: immunoblots demonstrating the effect of AG 1478 on activation of ERK and p70S6 kinase. AVP treatment activated both ERK (top) and p70S6 kinase (bottom), whereas pretreatment with AG1478 (20 M) inhibited activation of both proteins. Total ERK was stained to demonstrate equal protein loading (middle). All these experiments were repeated at least twice with similar results. been shown to stimulate p70S6 kinase in mesangial cells.
The role of p42/p44 MAPK (ERK2/1) in the transduction of proliferative signals to the nucleus is well known (39, 43) . ERK is activated by receptor tyrosine kinases (e.g., growth factors) and by stimulation of GPCRs (e.g., V 1 ) (34). Binding of ligand transduced proliferative or differentiation signals to the nucleus resulting in activation of cyclin-dependent kinases and cell cycle progression (24) . The signaling pathways leading from activated growth factor receptors to ERKs showed that the small GTPase Ras played a prominent role (15, 31) . Because full activation of ERK requires both threonine and tyrosine phosphorylation, it suggested that integration of multiple signaling pathways was required for the activation of the kinase (28) . In accordance with previously published data, our results indicate that AVP-induced mesangial cell growth was dependent on ERK phosphorylation, because inhibition of ERK activation by PD-98059 inhibited AVPinduced proliferation. However, our data also show, for the first time in mesangial cells, that the PI3K pathway plays an important role in AVP-induced proliferation.
PI3K signaling through p70S6 kinase acts synergistically with Ras/MAPK to stimulate the G1 to S-phase transition of the cell cycle (7, 30) . PI3K is composed of two subunits (regulatory p85 and catalytic p110) that appear to possess both lipid kinase and protein kinase activities (9, 13) . PI3K activation occurs after binding of p85, through its SH2 domain, to the cytoplasmic region of receptor tyrosine kinases, which recruit p110 to the plasma membrane where the lipid substrates are localized. Also, GTP-bound Ras can bind to and activate PI3K (38) . p70S6 kinase is a prominent downstream effector of PI3K (26) . Cell proliferation requires the coordinate activation of p70S6 kinase. This kinase participates in the translation of mRNAs that encode many of the components of the translational apparatus, including ribosomal proteins and elongation factors. Thus activation of p70S6 kinase is a prerequisite for protein synthesis (17) . p70S6 kinase is activated in vivo by phosphorylation, mediated, in part, by PI3K and by a phosphatidylinositol kinase-related kinase, mTOR (2, 17, 26) . Rapamycin inhibits mTOR and prevents it from activating p70S6 kinase by forming a stable complex with FK506 binding protein, which binds mTOR (5) . Results presented in this report show that both rapamycin and LY-294002, which inhibit PI3K directly, potently inhibited control and AVPstimulated mesangial cell proliferation, indicating the importance of p70S6 kinase activation in mesangial cell proliferation.
PI3K activation is important not only in cell proliferation but also in cell survival. A second PI3K effector, Akt, also known as protein kinase B, is also affected by growth factors and plays a role in cell survival (6) . Activation of Akt and p70S6 kinase by a similar range of mitogens and phosphatase inhibitors implied a close connection between the signaling pathways to the two kinases. Earlier studies suggested that p70S6 kinase activation was mediated by Akt; however, it now appears that p70S6 kinase can be activated independently of Akt (reviewed in 17, 11, 35) . Our results do not allow us to conclude whether p70S6 kinase activation is dependent on Akt or not; rather, it demonstrates the importance of the PI3K signaling pathway and p70S6 kinase activation in AVP-stimulated mesangial cell proliferation.
Although AVP-induced MAPK activation has been reported (1), the mechanism by which AVP activates MAPK and PI3K signaling cascades leading to cell growth was not previously known. GPCR transactivation of receptor tyrosine kinases was shown to be necessary for transmission of mitogenic and other signals to the nucleus (12) . Data presented in this paper indicated for the first time that the EGF-R was potently activated by AVP stimulation. In addition, this activation was inhibited by the EGF-R kinase inhibitor AG 1478. As further proof of the involvement of EGF-R in AVP-induced cell signaling, AG 1478 inhibited both AVP-induced cell proliferation as well as MAPK and PI3K activation. In this paper, we suggest that AVPstimulated EGF-R activation is induced by intracellular signals. There is presently no evidence of EGF-R ligand (EGF or TGF␣) precursor production stimulated by AVP, as has been shown in other models (37, 55) . Future studies will reveal the feasibility of such pathways of AVP-induced EGF-R transactivation.
We have previously shown that AVP induces Ca 2ϩ mobilization and PKC activation in mesangial cells (4, 47) . We therefore tried to determine whether EGF-R activation by AVP takes place in a Ca 2ϩ /PKC-dependent manner. Eguchi et al. (18) showed that the Ca 2ϩ / PKC-sensitive, nonreceptor tyrosine kinase Pyk2 was activated after ANG II treatment in vascular smooth muscle cells. We have shown here that AVP also induced Pyk2 activation in mesangial cells, suggesting that AVP-induced EGF-R activation is mediated by Pyk2. Both Pyk2 and EGF-R formed complexes with c-Src, suggesting a role for c-Src in Pyk2-mediated EGF-R transactivation by AVP. Further studies using EGF-R mutants lacking c-Src binding domains will reveal the importance of c-Src binding in EGF-R activation. Our results suggest that EGF-R serves as a scaffold for preactivated c-Src and for downstream adaptors that lead to MAPK and PI3K activation in mesangial cells treated with AVP. This is in accordance with the mechanism of MAPK activation by ANG II in smooth muscle cells suggested by Eguchi et al. (19) .
In conclusion, in this report we have attempted to elucidate the mechanism by which AVP induces mesangial cell proliferation. We have previously shown that AVP binding to mesangial cells results in activation of PKC and elevation in intracellular levels of Ca 2ϩ (4, 47) . We now show that within 30 s of AVP treatment, the protein tyrosine kinase Pyk2 is tyrosine phosphorylated (activated), resulting in its association with and activation of c-Src by 1-5 min. This results in Src/EGF-R association with activation of EGF-R within 15 min of AVP treatment, leading to MAPK and p70S6 kinase activation and cell proliferation (a scheme is presented in Fig. 6 ). These studies may be important for the future development of therapies for treatment of glomeruloproliferative diseases.
